CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Definium Therapeutics, Inc.
Sign in to watch- Ticker
- DFTX
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- 212-220-6633
- Business address
- ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
- Former names
- Mind Medicine (MindMed) Inc.
- 8-K Event Regulation FD disclosure · Other events
- 8-K Event Other events
- 4 Planned sale Chief Executive Officer sold 19,023 shares at $37.94 ($721,733)
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Grant or award Chief Executive Officer acquired 375,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 100,000 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 62,500 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 62,500 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 62,500 shares (grant or award)
- 8-K Event Regulation FD disclosure · Other events
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale Chief Legal Officer sold 13,008 shares at $45.03 ($585,750)
- 4 Planned sale Chief Financial Officer sold 3,013 shares at $45.03 ($135,675)
- 4 Planned sale Chief Executive Officer sold 29,208 shares at $45.03 ($1,315,236)
- 4 Planned sale Chief Medical Officer sold 10,035 shares at $45.03 ($451,876)
- 4 Planned sale Chief Commercial Officer sold 2,867 shares at $45.03 ($129,101)
- 144 Insider Sale of Securities
Page 2 of 26 · 506 filings